AMP-activated protein kinase (AMPK) serves as the master regulator of mitochondrial quality control, coordinating mitochondrial biogenesis, mitophagy (selective autophagy of mitochondria), and mitochondrial dynamics (fusion and fission) to maintain cellular bioenergetic homeostasis[1]. In neurodegenerative diseases, AMPK dysfunction disrupts every facet of mitochondrial quality control, leading to the accumulation of dysfunctional mitochondria, impaired energy production, and neuronal death characteristic of Alzheimer's disease, Parkinson's disease, and related disorders[2]. This page explores the molecular mechanisms by which AMPK governs mitochondrial health and how its dysregulation contributes to neurodegeneration.
AMPK is a heterotrimeric kinase consisting of:
| Trigger | Mechanism | Cellular Context |
|---|---|---|
| AMP/ATP ratio ↑ | Direct AMP binding to γ subunit | Energy stress |
| LKB1 (STK11) | Primary upstream kinase | Tumor suppressor |
| CaMKKβ | Calcium-dependent activation | Synaptic activity |
| TAK1 | Stress-activated kinase | Inflammatory stress |
AMPK directly phosphorylates and activates PGC-1α (PPARGC1A), the master regulator of mitochondrial biogenesis:
AMPK also activates mitochondrial biogenesis through:
AMPK directly phosphorylates ULK1 (unc-51 like autophagy activating kinase 1), initiating mitophagy:
| ULK1 Site | AMPK Phosphorylation | Effect |
|---|---|---|
| Ser317 | Direct phosphorylation | Initiates autophagy |
| Ser555 | Direct phosphorylation | Activates ULK1 complex |
| Ser637 | Indirect (via SIK3) | Promotes mitophagy |
Upon AMPK activation:
AMPK enhances the PINK1-Parkin mitophagy pathway:
| AMPK Effect | Mechanism | Outcome |
|---|---|---|
| PINK1 stabilization | AMPK phosphorylates PINK1 | Enhanced mitophagy initiation |
| Parkin activation | Direct phosphorylation | Increased ubiquitination |
| Optineurin recruitment | Phosphorylation enhances binding | Efficient cargo recognition |
AMPK promotes mitochondrial fission through:
| Target | Mechanism | Outcome |
|---|---|---|
| DRP1 (DNM1L) | Phosphorylation at Ser616 | GTPase activation, fission |
| MFF | Upregulation | Fission receptor recruitment |
| Fis1 | Transcriptional upregulation | Fission complex assembly |
AMPK indirectly promotes fusion through:
In neurodegeneration:
| AMPK-Mitochondrial Defect | Consequence |
|---|---|
| Reduced AMPKα2 activity | Impaired mitochondrial biogenesis |
| Decreased PGC-1α | Reduced mitochondrial density |
| Impaired DRP1 fission | Abnormal mitochondrial morphology |
| Failed mitophagy | Aβ-induced mitochondrial dysfunction |
Key mechanisms:
| AMPK-Mitochondrial Defect | Consequence |
|---|---|
| LRRK2 G2019S inhibits AMPK | Severe mitophagy impairment |
| PINK1/Parkin pathway failure | Impaired clearance of damaged mitochondria |
| Reduced TFAM | Decreased mitochondrial DNA copy number |
| Complex I deficiency | Energy crisis in dopaminergic neurons |
Therapeutic implications:
| AMPK-Mitochondrial Defect | Consequence |
|---|---|
| Reduced AMPK in motor neurons | Energy crisis |
| SOD1 mutations impair AMPK | Mitochondrial dysfunction |
| C9orf72 repeats affect mitophagy | Stress granule formation |
| AMPK-Mitochondrial Defect | Consequence |
|---|---|
| Mutant huntingtin disrupts AMPK | Impaired biogenesis |
| Reduced PGC-1α expression | Mitochondrial deficiency |
| Impaired mitophagy | Aggregate accumulation |
| Compound | Mechanism | Clinical Status | Notes |
|---|---|---|---|
| Metformin | Complex I inhibition → AMPK | Approved (diabetes) | AD/PD trials ongoing |
| AICAR | Direct AMPK agonist | Research | Poor BBB penetration |
| A-769662 | Direct allosteric activator | Preclinical | β1-selective |
| PT1 | Indirect activator | Research | Oral bioavailability |
| Exendin-4 | GLP-1 agonist → AMPK | Approved (diabetes) | Neuroprotective |
| Compound | Target | Status |
|---|---|---|
| PGC-1α agonists | PGC-1α | Preclinical |
| SIRT1 activators | SIRT1 | Research |
| NAD+ precursors | NAD+ levels | Clinical trials |
| Compound | Mechanism | Status |
|---|---|---|
| Rapamycin | mTOR inhibition → ULK1 | Preclinical |
| Urolithin A | Mitophagy induction | Clinical trials |
| Nicotinamide | NAD+ boost → SIRT1 | Research |
Herzig et al. 'AMPK: The energy sensor for mitochondrial quality control (2024)'. 2024. ↩︎
Cai et al. AMPK dysfunction in neurodegenerative diseases (2023). 2023. ↩︎